Abstract
In order to investigate the antianginal effects of celiprolol (NBP-582), a randomized double-blind crossover study controlled with placebo was carried out in 17 patients with stable effort angina pectoris. Multistage treadmill exercise testing was performed before and at 4, 7, and 24 hr after a single oral administration of 400mg celiprolol or placebo. The exercise testing was terminated at moderate angina pain.
The treadmill exercise duration showed no statistically significant time effects or order effects either before or after administration of the test drugs.
Celiprolol significantly prolonged exercise duration, time to angina, and time to onset of ST-segment depression≥0.1mV at 4, 7, and 24hr after administrationin comparison with placebo. However, there was no significant difference in time to angina disappear ance at 4, 7, and 24 hr after administration between celiprolol and placebo.
Celiprolol significantly reduced systolic blood pressure at rest in a standing position and peak exercise, and peak exercise at 4 and 7hr after administration respectively in comparison with placebo. At 24hr after administration, tendency of reduction of systolic blood pressure was observed at peak exercise.
There was no significant difference in diastolic blood pressure at 4, 7, and 24hr after administration between celiprolol and placebo. Celiprolol significantly reduced heart rate and pressure rate product (PRP) at peak exercise at 4, 7, and 24hr after administration in comparison with placebo.
No significant difference in ST deviation was observed at peak exercise at 4, 7, and 24hr after administration between celiprolol and placebo. A tendentious or significant prolongation of alleviated exercise-induced ST depression (ST SXT) was observed at 4hr or at 7and 24hr after administration.
Celiprolol significantly reduced heart rate, PRP, and ST deviation during exercise over 24hr.
These results indicate that celiprolol significantly increases exercise tolerance in patients with stable effort angina pectoris over 24hr after a single oral administration of 400mg. It is concluded that celiprolol is a clinically useful antianginal agent.
